leadf
logo-loader
viewHumanigen, Inc.

Humanigen wins US patent for Lenzilumab in preventing cytokine storm and neurotoxicity related to CAR-T cell therapy

CEO Cameron Durrant said the patent underscores the value of the firm's "robust pipeline" across the many disease areas where cytokine storm plays a critical role, including "COVID-19 and acute graft-versus-host disease"

Cameron - Humanigen wins US patent for Lenzilumab in preventing cytokine storm and neurotoxicity related to CAR-T cell therapy
The patent covers the use of lenzilumab to prevent, or treat cytokine release syndrome, neurotoxicity and reduce incidence or severity of CAR-T-related toxicities in patients undergoing CAR-T cell therapy

Humanigen Inc (NASDAQ:HGEN) announced on Monday that the US Patent and Trademark Office has issued a patent to the company for the use of its lead drug candidate lenzilumab in preventing and treating an immune hyper-response called cytokine storm and neurotoxicity in patients undergoing chimeric antigen receptor T (CAR-T) cell therapy.

The Burlingame, California-based clinical stage biopharmaceutical company said the patent covers the use of lenzilumab to prevent or treat cytokine release syndrome (CRS), neurotoxicity and otherwise inhibit or reduce incidence or severity of CAR-T-related toxicities in patients undergoing CAR-T cell therapy.

The company explained that Lenzilumab binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), which has been identified as a “key initiator” of the “inflammatory cascade triggering CAR-T cell therapy-related toxicities, such as cytokine release syndrome” and neurotoxicity, which have been associated with prolonged hospitalization and intensive care unit stay.

READ: Humanigen says first patient dosed in NIH-run ACTIV-5 ‘Big Effect Trial’ evaluating lenzilumab for COVID-19

“We believe lenzilumab can potentially play an important role in enhancing CAR-T cell therapy, and we are committed to advancing the development of lenzilumab to address cytokine storm associated with CAR-T cell therapy and other areas,” Humanigen CEO Cameron Durrant said in a statement.

“This patent underscores Humanigen’s pioneering approach to neutralizing GM-CSF with lenzilumab and the value of our robust pipeline across the many disease areas where cytokine storm plays a critical role, including COVID-19 and acute graft-versus-host disease,” he added.

The patent, titled “Methods of Treating Immunotherapy-Related Toxicity Using a GM-CSF Antagonist,” was issued on December 22, 2020 as US Patent No. 10,870,703.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive

Quick facts: Humanigen, Inc.

Price: - -

OTCMKTS:HGEN
Market: OTCQB
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Humanigen chosen by National Institute of Health's upcoming coronavirus...

Humanigen Inc (OTCQB:HGEN) CEO Cameron Durrant tells Proactive that its lead drug candidate lenzilumab was selected for use in the National Institute of Health’s upcoming coronavirus trial. Durrant says lenz will be evaluated in the National Institute of Allergy and Infectious Diseases’...

on 07/31/2020

2 min read